Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.
Actively Recruiting
Researchers are evaluating how well vortioxetine, given at doses of 10 mg or 20 mg daily, works compared to a placebo for treating depression symptoms in Japanese teenagers aged 12 to 17 years diagnosed with Major Depressive Disorder MDD. The study aims to assess both the effectiveness and side effects of the medication in this population. Participants will take either vortioxetine or a placebo orally once a day for 14 weeks. The treatment starts at 10 mg per day and may be increased to 20 mg per day. After the treatment period, there is a 4-week phase to monitor for any side effects. The study includes a total of 13 clinic visits during the participation period. Throughout the study, participants will be regularly assessed using various tools including the Children Depression Rating Scale Revised version CDRS-R, Patient Health Questionnaire-9 for Adolescents PHQ-A, Digit Symbol Substitution Test DSST, and Clinical Global Impression scales. Blood samples will be taken to measure plasma levels of vortioxetine. The entire participation lasts about 20 weeks, including up to 2 weeks for screening, 14 weeks of treatment, and 4 weeks of post-treatment follow-up to check safety.
Actively Recruiting
Researchers are evaluating KarXT for the treatment of schizophrenia in adolescents aged 13 to 17 years. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of KarXT in this population experiencing active symptoms of psychosis. The study is sponsored by Bristol-Myers Squibb and focuses on improving schizophrenia symptoms as measured by standard clinical scales. Participants will be randomly assigned to receive either KarXT or a matching placebo with specified doses on designated days. The study uses a parallel design with quadruple masking to compare outcomes between the two groups. The primary treatment phase lasts 5 weeks, during which the effects of KarXT on schizophrenia symptoms will be closely monitored. During the study, participants will undergo assessments including the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression-Severity CGI-S, and Childrens Global Assessment Scale CGAS at baseline and Week 5. These measures track changes in symptom severity and overall functioning. Safety and tolerability will also be evaluated throughout the trial, which is expected to complete by December 2029.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.